选择高血压的初始治疗方法
1Department of Internal Medicine and the Hypertension Division, University of Texas Southwestern Medical Center, Dallas 75235-8899, USA.
JAMA
|May 22, 1996
概括
管理高血压需要改变生活方式和药物治疗. 目前的指导方针建议在轻度病例中服用利尿剂或β抑制剂,优先考虑中风和心血管风险降低. 患者特异性因素指导最佳治疗选择.
科学领域:
- 临床医学 临床医学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 高血压是一种普遍的疾病,需要谨慎管理.
- 准确的高血压诊断和治疗选择仍然具有挑战性.
- 对抗高血压药物的推不断变化,需要更新临床指导.
研究的目的:
- 总结目前对高血压治疗的建议.
- 强调饮食,运动和特定药物的作用.
- 在抗高血压疗法选择中强调个性化的患者护理.
主要方法:
- 关于检测,评估和治疗高血压的联合国家委员会第五份报告的审查.
- 对支持初始治疗策略的结果研究的分析.
- 考虑除了疗效之外的其他因素,如患者的病情和药物费用.
主要成果:
- 建议在初始的轻度高血压治疗中进行饮食和运动.
- 如果需要,建议使用利尿剂或β-阻断剂作为后续步骤.
- 有证据支持这些药物可以减少中风和心血管事件.
结论:
- 轻度高血压的初始治疗应侧重于改变生活方式.
- 药理治疗应以结果研究的证据为指导.
- 考虑患者需求和药物成本的个性化治疗计划对于最佳高血压管理至关重要.
更多相关视频
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Hypertension I: Introduction
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Hypertension V: Nursing Management
The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


